NCT00000819View on ClinicalTrials.gov

A Phase II Randomized, Double-Blind, Placebo-Controlled Trial to Determine the Efficacy of Prednisone Therapy in HIV-Associated Nephropathy (HIVAN)

PHASE2CompletedINTERVENTIONAL
Enrollment

54

Participants

Timeline

Start Date

Not specified

Study Completion Date

September 30, 1996

Conditions
HIV InfectionsAIDS-Associated Nephropathy
Interventions
DRUG

Prednisone

Trial Locations (8)

10003

Beth Israel Med. Ctr. (Mt. Sinai), New York

21287

Johns Hopkins Adult AIDS CRS, Baltimore

44106

Case CRS, Cleveland

44109

MetroHealth CRS, Cleveland

46202

Indiana Univ. School of Medicine, Infectious Disease Research Clinic, Indianapolis

90095

UCLA CARE Center CRS, Los Angeles

90502

Harbor-UCLA Med. Ctr. CRS, Torrance

Unknown

Ucsf Aids Crs, San Francisco

Sponsors

Collaborators (1)

Upjohn
All Listed Sponsors
collaborator

Upjohn

INDUSTRY

lead

National Institute of Allergy and Infectious Diseases (NIAID)

NIH

NCT00000819 - A Phase II Randomized, Double-Blind, Placebo-Controlled Trial to Determine the Efficacy of Prednisone Therapy in HIV-Associated Nephropathy (HIVAN) | Biotech Hunter | Biotech Hunter